

## Special Issue

# Clinical and Preclinical Development of Bacterial Vaccines

### Message from the Guest Editors

The global threat of antimicrobial resistance (AMR) has been identified by the World Health Organization as one of the three greatest threats to human health; annual deaths related to AMR are currently ~700,000, and are projected to rise to 10 million by 2050. New antibiotics cannot solve the problem, as bacteria quickly adapt and develop new resistance mechanisms. Therefore, there is an urgent need for the development of vaccines against AMR. Bacterial vaccines are used for managing bacterial diseases. They reduce the incidence of resistant and susceptible infections, as well as antibiotic consumption. Advances in vaccine technology in recent decades have made it possible to develop vaccines against previously challenging targets. There is a need to understand which vaccines are currently being developed and which may serve as tools to help control AMR in the future. The aim of this Special Issue is to investigate bacterial vaccine candidates in preclinical and clinical development against pathogens, some of the main advances made, new techniques and methods for vaccine development, and vaccine benefits and drawbacks.

### Guest Editors

Dr. Naeem Khan

Center for Immunobiology, WMU Homer Stryker MD School of Medicine, Kalamazoo, MI 49007-7000, USA

Dr. Ajay S. Akhade

Institute for Systems Biology, University of Washington, Seattle, WA 98109, USA

### Deadline for manuscript submissions

closed (23 November 2023)



## Vaccines

an Open Access Journal  
by MDPI

Impact Factor 3.4  
CiteScore 9.9  
Indexed in PubMed



[mdpi.com/si/146348](https://mdpi.com/si/146348)

*Vaccines*  
Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland  
Tel: +41 61 683 77 34  
[vaccines@mdpi.com](mailto:vaccines@mdpi.com)

[mdpi.com/journal/  
vaccines](https://mdpi.com/journal/vaccines)





# Vaccines

---

an Open Access Journal  
by MDPI

---

Impact Factor 3.4  
CiteScore 9.9  
Indexed in PubMed



[mdpi.com/journal/  
vaccines](https://mdpi.com/journal/vaccines)



## About the Journal

### Message from the Editor-in-Chief

*Vaccines* (ISSN 2076-393X) has had a 6-year history of publishing peer-reviewed state of the art research that advances the knowledge of immunology in human disease protection. Immunotherapeutics, prophylactic vaccines, immunomodulators, adjuvants and the global differences in regulatory affairs are some of the highlights of the research published that have shaped global health. Our open access policy allows all researchers and interested parties to immediately scrutinize the rigorous evidence our publications have to offer. We are proud to present the work and perspectives of many to contribute to future decisions concerning human health.

---

### Editor-in-Chief

Prof. Dr. Ralph A. Tripp

Department of Infectious Diseases, College of Veterinary Medicine,  
University of Georgia, Athens, GA 30602-7387, USA

---

### Author Benefits

#### High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPIus / SciFinder, and other databases.

#### Journal Rank:

JCR - Q2 (Medicine, Research and Experimental) /  
CiteScore - Q1 (Pharmacology (medical))

#### Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 19.6 days after submission; acceptance to publication is undertaken in 2.8 days (median values for papers published in this journal in the first half of 2025).